Fundz

Vicebio raised $100M in Series B financing led by TCGX to accelerate development of multivalent respiratory virus vaccines.

PRIVATESep 23, 2024

Amount Raised

$100 Million

Round Type

Series B

LondonBiotechnologyHealth CareTherapeuticsBiopharma

Investors

MedicxiUni QuestVen BioAvoro VenturesGoldman Sachs AlternativesTcgx

Description

Vicebio, a London-based biopharmaceutical company, raised $100M in Series B funding led by TCGX. The funds will be used to accelerate the development of multivalent respiratory virus vaccines using proprietary molecular clamp technology.

Quick answer

Vicebio Ltd raised $100 Million in a Series B round, dated September 23, 2024. Investors: Medicxi, Uni Quest, Ven Bio, Avoro Ventures, Goldman Sachs Alternatives and Tcgx. Vicebio Ltd is based in London, England, United Kingdom.

How much did Vicebio Ltd raise?
Vicebio Ltd raised $100 Million in a Series B round on September 23, 2024.
Who invested in Vicebio Ltd?
Medicxi, Uni Quest, Ven Bio, Avoro Ventures, Goldman Sachs Alternatives and Tcgx are named as investors in this round.
What does Vicebio Ltd do?
Vicebio Ltd is a biopharmaceutical company that specializes in developing next-generation vaccines against respiratory viral infections.
Where is Vicebio Ltd based and how big is it?
Vicebio Ltd is based in London, England, United Kingdom.
Who are the decision-makers at Vicebio Ltd?
Fundz holds 1 contact at Vicebio Ltd. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Vicebio Ltd, and when

A new round usually means Vicebio Ltd is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vicebio Ltd raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vicebio Ltd, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vicebio Ltd. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vicebio Ltd

Location

London, England, United Kingdom

About

Vicebio Ltd is a biopharmaceutical company that specializes in developing next-generation vaccines against respiratory viral infections. It utilizes proprietary Molecular Clamp technology to enhance immune responses and production efficiency. Established by Medicxi, Vicebio aims to address significant health burdens associated with respiratory viruses. The company is currently in clinical trials for its vaccine candidates.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vicebio Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Vicebio Ltd's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Vicebio Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.